Search

Madrigal Pharmaceuticals Inc

Cerrado

SectorSanidad

504.29 -0.26

Resumen

Variación precio

24h

Actual

Mínimo

493.97

Máximo

509.2

Métricas clave

By Trading Economics

Ingresos

36M

-58M

Ventas

53M

364M

BPA

-1.99

Margen de beneficios

-15.906

Empleados

915

EBITDA

30M

-56M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+35.81% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-803M

12B

Apertura anterior

504.55

Cierre anterior

504.29

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

73 / 340 Clasificación en Healthcare

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13 ago 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12 ago 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10 ago 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7 ago 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6 ago 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4 ago 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3 ago 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31 jul 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30 jul 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 jul 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 jul 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 jul 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 jul 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

35.81% repunte

Estimación a 12 Meses

Media 689.08 USD  35.81%

Máximo 962 USD

Mínimo 543 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

12

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

73 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat